echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Two thirds of type 2 diabetic patients have cardiovascular risk factors or experience cardiovascular events

    Two thirds of type 2 diabetic patients have cardiovascular risk factors or experience cardiovascular events

    • Last Update: 2018-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The International Diabetes Federation (IDF) global survey shows that cardiovascular disease (CVD) is the leading factor leading to disability and death in patients with type 2 diabetes Although the incidence rate is high, 1/4 type 2 diabetes patients have never discussed their CVD risk factors with doctors, or can not recall the relevant discussions -The first global IDF survey on CVD cognition of patients with type 2 diabetes received more than 12000 responses in more than 130 countries September 29, 2018 / AP / -- to commemorate the world heart day on September 29, the International Diabetes Federation (IDF) and Novo Nordisk published the results of the "taking diabetes to heart" survey The global survey investigated the cardiovascular disease (CVD) cognition in 12695 patients with type 2 diabetes The results showed that type 2 diabetes mellitus (2/3) had CVD risk factors such as hypertension, poorly controlled blood glucose levels and high cholesterol, or CVD events such as angina pectoris, myocardial infarction, stroke or heart failure However, a quarter of the respondents never discussed the risk factors of CVD with doctors or could not recall the relevant discussions, and only a quarter of the respondents thought their cardiovascular risk was low Commenting on the findings, Professor Nam h CHO, President of IDF, said: "these findings confirm our concerns about the rise in the prevalence of diabetes and its related complications around the world Unfortunately, awareness of diabetes related risks and their consequences is still very low, and education on diabetes complications is very lacking We call on governments to invest in early detection of type 2 diabetes to ensure that medical professionals are trained to guide people to actively change their lifestyles and better manage their own diabetes This will help prevent diabetes complications that can lead to disability or even life-threatening conditions " At present, there are 425 million adult diabetes patients in the world, most of them are type 2 diabetes CVD, including stroke, coronary heart disease and peripheral artery disease, is the leading cause of disability and death in patients with type 2 diabetes In the "heart pregnant diabetes" survey, 3 / 4 of patients with type 2 diabetes expressed trust in CVD related information provided by doctors More than half of the respondents said they need to learn more about the risk factors associated with CVD to better understand these risk factors, so as to help them prevent these factors "Cardiovascular disease can have a devastating impact on the lives of people with type 2 diabetes and their families." Professor Stephen Gough, global chief medical officer of Novo Nordisk, said "The results of the IDF survey are very impressive and further highlight the importance of raising awareness of the risk of CVD and its impact on patients with type 2 diabetes We are committed to continuing to work with IDF to use the above global findings to store information for future work so that it can further improve health outcomes " A comprehensive report will be produced at the end of "heart with diabetes", including specific regional and country survey results and related resources, to support efforts to improve knowledge level and cognition in patients with type 2 diabetes and people at risk around the world Reference 1 Low Wang CC, Hess CN, Hiatt WR, et al Clinical update: cardiovascular release in diabetes instruments: atherosclerotic cardiovascular release and heart failure in type 2 diabetes instruments - mechanisms, management, and clinical considerations Circulation 2016; 133:2459-2502 2 International Diabetes Federation Taking Diabetes to Heart Survey Results [Placeholder] 3 International Diabetes Federation IDF Diabetes Atlas 8th edition Brussels, Belgium 2017 Available at: http:// Last accessed: September 2018 4 International Diabetes Federation Diabetes and cardiovascular disease 2016 Available at: Last accessed: September 2018 About the survey of "heart with diabetes" and the survey of "heart with diabetes" -- The first online Multi Country survey was conducted to investigate the knowledge and knowledge of cardiovascular disease in patients with type 2 diabetes The participants in this survey come from more than 130 countries and regions around the world and have received more than 12000 responses This investigation has now been completed The findings will be used in policy-making and decision-making processes for severe diabetic complications The International Diabetes Federation (IDF) is an international industry organization with more than 240 National Diabetes organizations in 168 countries and regions It represents the interests of the growing number of diabetic patients and high-risk groups Since 1950, IDF has been playing a leading role in the global diabetes community The purpose of IDF activities is to influence decision-making, enhance public awareness and encourage improvement, promote the exchange of high-quality diabetes information, and provide education for diabetes patients and their medical service providers Www.idf.org About Novo Nordisk: Novo Nordisk, with a history of 95 years, is a company committed to innovation and a leader in diabetes This tradition also gives us experience and ability to help people overcome other serious chronic diseases, such as hemophilia, growth hormone disorders and obesity Headquartered in Copenhagen, Denmark, Novo Nordisk has about 43100 employees in 79 countries and regions around the world, providing products and services to more than 170 countries and regions around the world.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.